References
- Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology48(1), 137–145 (2008).
- El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology126, 460–468 (2004).
- Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care29, 2701–2707 (2006).
- Donadon V, Balbi M, Ghersetti M et al.Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol.28, 2506–2511 (2009).
- Sloan FA, Bethel A, Ruiz D, Shea AH, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch. Intern. Med.168, 192–199 (2008).
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care27(1), S5–S10 (2004).
- Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res.35, 694–704 (2003).
- Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. Diabetes Care24, 843–849 (2001).
- Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle8, 88–96 (2009).
- Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract. Res. Clin. Endocrinol. Metab.22, 625–638 (2008).
- Jiralerspong S, Giordano SH, Meric-Bernstam F et al.The effects of metformin on pathologic complete response rates in diabetic breast cancer patients receiving neoadiuvant systemic therapy. Proceedings of ASCO. J. Clin. Oncol.26(20), abstract 528 (2008).
- Cox M, Gleave M, Zakikhani M. Insulin receptor expression by human prostate cancers. Prostate69, 33–40 (2009).